Researchers found that blocking the activity of IL-6 at the blood-brain barrier increased the lifespan of fruit flies with cancer by 45% and also found that after 21 days, 75% of cancer-carrying lab mice treated with an IL-6 receptor blocker were alive, versus only 25% of untreated mice.
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Research highlights from ESMO21 included results from Phase III DESTINY-Breast03 trial (AZ, Daiichi Sankyo), Phase II KRYSTAL-1 lung cancer study (Mirati Therapeutics), Phase III CheckMate 649 (Bristol Myers Squibb), and the Phase III KEYNOTE-826 trial.
A specialized hydrogel can not only encapsulate and protect mRNA cancer vaccines from being broken down in the body, but can also target lymph nodes to activate immune cells, shows early stage research.
The nanobodies, which bind tightly to the SARS-CoV-2 virus, neutralizing it in cell culture, could provide a cheaper and easier to use alternative to human antibodies taken from patients who have recovered from COVID-19.
AI-based cancer imaging diagnostics have improved enormously over the last few years, with some programs already in use in the clinic, but researchers advise caution with more widespread rollout until more large-scale testing is completed.
A new genomics program in South Carolina will enroll 100,000 volunteers over 4 years who will undergo exome testing to provide useful health information to the patients and their clinicians from the start, while also contributing to medical research.
According to the study, one-in-six adults (17.3%) had at least one pathogenic genetic variant. When integrated with deep phenotyping that included imaging, blood test and other analytical methods, one-in-nine (11.9%) had genotype and phenotype associations, supporting the clinical diagnosis of a genetic disorder.
In this eBook, sponsored by Qiagen, we explore the opportunities and challenges of precision oncology and how molecular profiling is fundamental not only to inform on tumor diagnosis and prognosis, but also to drive therapeutic decisions in routine clinical care.
The VITAL Act would update federal lab standards under the Clinical Laboratory Improvement Amendments (CLIA), overseen by the U.S. Department of Health and Human Services (HHS)—through which LDTs would also be regulated under the Public Health Services Act, which gives HHS authority to respond to public health emergencies.